Senile plaques comprised of Aβ peptides are a hallmark of Alzheimer's disease (AD) brain, as are activated glia that release inflammatory molecules, including eicosanoids. Previous studies have demonstrated that amyloid precursor protein (APP) and Aβ levels can be increased through activation of thromboxane A2-prostanoid (TP) receptors on neurons. We demonstrate that TP receptor regulation of APP expression depends on Gα q -signaling and conventional protein kinase C isoforms. Importantly, we discovered that Gα q -linked prostaglandin E2 and leukotriene D4 receptors also regulate APP expression. Prostaglandin E2 and thromboxane A2, as well as total APP levels, were found to be elevated in the brains of aged 5XFAD transgenic mice harboring Aβ plaques and activated glia, suggesting that increased APP expression resulted from eicosanoid binding to Gα q -linked neuronal receptors. Notably, inhibition of eicosanoid synthesis significantly lowered brain APP protein levels in aged 5XFAD mice. These results provide new insights into potential AD therapeutic strategies.
1
. These plaques are thought to contribute, either directly or indirectly, to the neuronal dysfunction and dementia associated with AD 2 . Other factors that are believed to contribute to AD pathogenesis include intracellular aggregates of hyperphosphorylated tau protein 3 , oxidative stress 4 , and neuroinflammation 5 . The inflammation observed in AD brain results largely from increased microglial activation in the vicinity of senile plaques 6, 7 and a number of glial-derived inflammatory molecules, including cytokines, chemokines and eicosanoids, as well as oxidizing molecules, have been suggested to exacerbate AD neuropathology 5, 8 . For example, isoprostane F2α III (iPF2α III), a lipid oxidation product thought to be elevated in AD brain 9, 10 , can activate the thromboxane A2 (TXA2)-prostanoid (TP) receptor on neurons with a resulting increase of APP mRNA stability that leads to enhanced APP expression and Aβ production 11, 12 . Similarly, TXA2 itself may also be increased in AD brain, as this eicosanoid is produced by activated microglia 13 . The signaling pathways that underlie the conversion of TP receptor activation into increases of APP expression and Aβ production have not been previously explored, and here we demonstrate the involvement of Gα q and conventional PKC isoforms. Importantly, we have discovered that activation of additional eicosanoid receptors, including those that bind prostaglandin E2 (PGE2) and leukotriene D4 (LTD4), also results in increased APP levels in receptor-transfected cells, as well as in primary rat or mouse neurons. As PGE2, TXA2, and LTD4 can be released from microglia 5, 14 , with the former shown to be elevated in the cerebrospinal fluid of AD patients 15, 16 , these studies further implicate glial inflammation in the pathogenesis of AD. An assessment of 5XFAD transgenic mice that develop Aβ plaques revealed an age-dependent elevation of PGE2 and TXA2, as well as APP. Importantly, inhibiting eicosanoid synthesis in aged 5XFAD mice led to significant diminutions of total APP levels and of Gα q involvement in promoting TP receptor-mediated increases in APP expression was further investigated by pre-incubation of IBOP-treated hTP-hAPP cells with the pan protein kinase C (PKC) inhibitor, Gο 6983 18 , to inhibit the activation of PKC downstream of Gα q . Cells were also treated with the Rho-associated protein kinase inhibitor, Y-27632 19 , which blocks signaling downstream of Gα 12/13 activation 20 . Only cells that were pretreated with Gο 6983 showed decreased APP mRNA, APP protein, and Aβ 1-40 (Supplementary Figure 1) following IBOP stimulation, whereas Y-27632 alone had no effect and its addition did not further increase the effect of Go6983. Although small amounts of Aβ 1-42 could be detected in the cellular medium, quantification was not reliable. In conclusion, these studies demonstrate that TP receptor activation of Gα q results in increased levels of APP mRNA and protein, as well as increased production of Aβ .
As the addition of Go6983 revealed that one or more PKC species appeared to be key mediators of TP receptor regulation of APP expression, studies were conducted to examine which specific isoform(s) of PKC are critical to this pathway. There are three broad classes of PKCs 21 : conventional cPKC isoforms that are activated by Ca ++ and diacylglycerol (DAG); novel nPKC isoforms that are activated by DAG, but are Ca ++ -insensitive; and atypical PKC isoforms that are insensitive to both DAG and Ca
++
, and are activated by other phospholipids. To determine which of the PKC classes are involved in the regulation of APP expression, hTP-hAPP cells were treated with the DAG mimic, phorbol 12-myristate 13-acetate (PMA) 22 , either alone or with the calcium ionophore, ionomycin (Iono) 23 . A significant increase in APP mRNA ( Fig. 2A) and protein ( Fig. 2B) , as well as in Aβ 1-40 production (Fig. 2C) , were observed upon PMA treatment. The co-treatment of cells with PMA plus ionomycin induced a greater increase of APP mRNA and APP protein expression than was observed with PMA alone (Fig. 2A,B) , and the effect of PMA alone or PMA plus ionomycin was blocked by Go6983. A similar trend was observed when Aβ 1-40 levels were monitored, although the ionomycin enhancement of the PMA effect was not clearly evident (Fig. 2C) . The enhanced APP expression observed with the Ca ++ ionophore in the presence of PMA suggests that it is primarily cPKC isoforms that are responsible for the effects on APP.
To further define the cPKC isoforms involved in the regulation of APP expression, select cPKC (α and β II) and nPKC (ε ) isoforms were knocked down via siRNA in hTP-hAPP cells. Efficient knockdown of the PKC isoforms was observed 72 h after transfection (see Supplementary Table 2) , and siRNA-treated cells were incubated in the presence of IBOP. Cells that were treated with siRNA directed against PKCε showed no decrease in APP protein expression (Supplementary Figure 2) relative to cells receiving control siRNA. Conversely, transfection with siRNA directed against PKCα or PKCβ II reduced the IBOP-induced increases in APP mRNA and protein, with PKCβ causing a greater reduction. Simultaneous PKCα and PKCβ II siRNA addition did not completely inhibit IBOP-induced increases in APP expression, perhaps due to the residual PKCα and PKCβ II that remain after knockdown, or because an additional cPKC isoform also contributes partially to the regulation of APP expression. Nonetheless, these findings further confirm that cPKCs are largely responsible for the effects of TP receptor activation on APP expression.
Additional Eicosanoid Receptors Regulate APP Expression. The aforementioned findings raised the question of whether other Gα q -coupled receptors, in addition to the TP receptor, might also affect APP levels. In particular, the compelling evidence of a connection between neuroinflammation and AD pathology prompted an investigation of additional Gα q -linked receptors that, like the TP receptor, are reported to be expressed on neurons and can be activated by inflammatory eicosanoids. This led to an evaluation of the PGE2 receptors, EP1 and EP3 24 , the LTD4 receptor, CysLT1 25 , and the LTB4 receptor, BLT1 26 . QBI293 cells stably-expressing hAPP were transfected with constructs encoding each of these receptors, and these cells were subsequently exposed to known agonists. Ligand activation of the EP1, EP3, and CysLT1 receptors, but not the BLT1 receptor, led to increases in APP mRNA (Fig. 3A) and protein (Fig. 3B) , as well as Aβ (Fig. 3C ). In the case of the EP1 and EP3 receptor-expressing cells, some Aβ (1-40) was produced in the absence of agonist, presumably due to a constitutive receptor activity. The lack of APP increase after BLT1 transfection was not the result of poor receptor expression, as qPCR analysis revealed the presence of appreciable transcript (Supplementary Table 3 ). Thus, activation of multiple Gα q -linked eicosanoid receptors results in enhanced APP expression and Aβ release. However, this does not appear to be a feature of all Gα q -coupled receptors, as activation of the BLT1 receptor or the unrelated Gα q -linked angiotensin I receptor (not shown) did not result in changes of APP expression.
Each of the inflammatory eiscosanoids that were found to increase APP expression were examined for their effects on primary rat hippocampal neuron cultures that were treated with an anti-mitotic (cytosine arabinoside) to deplete dividing, non-neuronal cells. Consistent with prior observations 11 , IBOP addition resulted in a significant increase of APP (Fig. 4A ) that could be blocked with the specific antagonist, CNDR-51280 [compound 5 in 12 ]. Treatment of the neurons with LTD4 or the PGE2 analogue, 17PGE2, also led to increased APP expression (Fig. 4B-D) . The LTD4-mediated increase of APP was effectively inhibited with the CysLT1 receptor antagonist, pranlukast 27 ( Fig. 4B) . Interestingly, the EP1 antagonist, ONO8711 28 , did not block the 17PGE2-induced elevation of APP (Fig. 4C) , whereas the EP3 antagonist, L798,106 29 , significantly inhibited the effect of 17PGE2 on APP expression (Fig. 4D) . These data thus imply that the EP3 receptor, but not the EP1 receptor, mediated the 17PGE2-triggered increase of APP expression in rat hippocampal neuron cultures.
The relative magnitude of the increase of APP expression in the rat neurons was similar upon activation of each of the eicosanoid receptors, suggesting a similar degree of intracellular signaling via cPKC isoforms. To examine this further, additional studies were conducted in which high concentrations of the receptor agonists were added singly, or concurrently, to rat hippocampal neuron cultures. The simultaneous addition of all three stimulatory eicosanoids did not increase APP expression beyond that observed when each of these agents was added individually (Fig. 5A) . A similar observation was made with primary mouse cortical neuron cultures (Fig. 5B) . Although the addition of saturating levels of multiple agonists to the eicosanoid receptors did not lead to additive increases of APP expression, concurrent treatment of rat hippocampal neurons with sub-saturating concentrations of IBOP and 17PGE2 resulted in an increase of APP expression relative to that obtained with each agonist added alone (Fig. 5C ). Evidence of Eicosanoid Enhancement of APP Expression in the 5XFAD Transgenic Mouse Model of AD. The discovery that multiple eiscosanoids could increase APP expression through interaction with neuronal receptors suggested that a vicious cycle may ensue in the AD brain, whereby initial glial activation by Aβ oligomers and/or plaques results in a release of inflammatory eicsosanoids that subsequently up-regulate APP and Aβ production. PGE2 is reported to be elevated within the CSF of AD patients 16 , and to further explore whether there are increased eicosanoid levels in a mouse model with Aβ plaques, we measured both PGE2 and the TXA2 metabolite, TXB2, in 5XFAD transgenic mice in which robust Aβ deposition and glial inflammation are observed with age 30 . The levels of PGE2 ( Fig. 6A ) and TXB2 ( Fig. 6B) were comparable in brain homogenates from 1.5-month old 5XFAD transgenic mice and age-matched non-transgenic littermates, an age where the 5XFAD mice show relatively little Aβ deposition 30 . In contrast, significant increases in these eicosanoids were observed in the brains of 6.5-month old 5XFAD mice, which have profound Aβ deposition 30 , relative to age-matched non-transgenic mice and to the younger 5XFAD mice (Fig. 6A,B ). Attempts were made to quantify LTD4 levels in 5XFAD mouse brain homogenates, but the amounts were below the level of detection by LC-MS/MS. The observation of an age-dependent increase of brain eicosanoids in 5XFAD mice suggested that there may be a comparable increase of APP expression in the older mice due to activation of neuronal receptors, as described above. Notably, total APP levels in the cortex and hippocampus were elevated approximately two-fold in 6-month old 5XFAD mice relative to younger mice ( Fig. 6C and Supplementary Figure 3) . The age-dependent increase in APP appeared to occur in both genders of 5XFAD mice, although the inclusion of only two female mice in both the 1.5-and 6-month old groups did not allow for a statistical comparison of age effect by gender. Interestingly, whereas a significant increase in APP levels was observed with antibodies that recognize α -and β -secretase cleaved APP (i.e., sAPP) as well as intact APP ( Fig. 6C ; 22C11 antibody and Supplementary Figure 3B ; Karen antibody), the age-dependent elevation in APP was not observed when only intact APP was measured with a COOH-terminal antibody ( Fig. 7 and Supplementary Figure 4 ; 5685 antibody). This suggested that there was an increase of sAPP in the older transgenic mice, and analysis of APP COOH-terminal fragments generated after α -and β -secretase cleavage of APP also revealed a significant increase in these fragments in the older 5XFAD mice (Fig. 7) . Notably, both the larger COOH-terminal fragment, which should correspond to the C99 fragment generated after β -secretase cleavage of APP, and the smaller C83 COOH-terminal fragment that results from α -secretase cleavage of APP 31 , are increased in the older 5XFAD mice. This commensurate increase of sAPP and both α /β -secretase-generated COOH-terminal fragments of APP in the 6.0-month old 5XFAD mice suggests that there is an overall increase of APP expression in the older mice, with the majority of the increased APP undergoing processing, rather than an elevation of sAPP species that results from slowed sAPP degradation or a specific change in activity of one of Figure 5 . Activation of eicosanoid receptors in primary neurons with saturating and sub-saturating concentrations of receptor agonists. Rat hippocampal neurons (A) or mouse cortical neurons (B) that were grown in culture for 14 days were treated for 2 days with vehicle or high concentrations of IBOP (100 nM), LTD4 (1 μ M), 17PGE2 (1 μ M), or the combination of these agonists (I + L + 17). In (C), rat hippocampal neurons were treated with vehicle or sub-saturating concentrations of IBOP (50 nM; IBOP(L)), 17PGE2 (0.5 μ M; 17PGE2(L)), or the combination of these agonists (I(L) + 17(L)). In addition, neurons were also treated with a high concentration of IBOP (100 nM; IBOP(H)). APP was quantified from immunoblots (22C11 antibody), and statistical analyses consisted of a mixed-effects model, with values representing estimates from the least squares means fit of the mixed procedure from 3-4 independent studies, with 2-3 replicates per study. Error bars represent SEM; *p<0.05, **p < 0.01; ***p < 0.001. the enzymes that cleaves APP. A future comparison of APP mRNA levels in young and aged 5XFAD mice would further strengthen this interpretation.
To confirm an involvement of eicosanoids in the regulation of APP in aged 5XFAD mice, we inhibited the key enzymes involved in their synthesis. PG and TX synthesis depends on the metabolic conversion of arachidonic acid to PGH2 by COX-1 and/or COX-2 32 , and we evaluated known COX inhibitors for their ability to achieve meaningful brain concentrations upon oral administration. Both the selective COX-1 inhibitor, SC-560 33 and the COX-2 inhibitor, rofecoxib 34 , demonstrated good brain exposures (brain/plasma drug ratios ≥ 0.3) after oral dosing. This led to the administration of a mixture of these two inhibitors in drinking water to 5.5-6-month old 5XFAD mice for 7 days, with a separate group of mice receiving vehicle only. The drug-treated group had appreciable levels of the two compounds in their brains (Supplementary Table 4 ) that resulted in a nearly complete reduction of PGE2 and TXB2 (Supplementary Figure 5 ). An evaluation of combined sAPP and intact APP species by immunoblotting with the 22C11 antibody revealed that the COX inhibitors caused a significant reduction of APP levels of approximately 30% within the cortex (Fig. 8A) and hippocampus (Fig. 8B) . Figure 6 . Aged 5XFAD transgenic mice show increased levels of PGE2 and TXB2, as well as APP. Whole hemisphere brain homogenates from 5XFAD mice and non-transgenic (non-Tg) littermates that were 1.5 or 6.5 months of age were analyzed by LC-MS/MS for (A) PGE2 and (B) TXB2 (n = 3-4 per group). In (C), the level of total APP expression in cortical and hippocampal brain homogenates from 1.5 month old and 6.0 month old 5XFAD mice was determined by immunoblotting (22C11 antibody), with normalization to GAPDH. Lane loading in the immunoblot was randomized for study blinding during quantification (n = 5 per group; 2 females (F) and 3 males (M) in each age group). Statistical analyses consisted of a one-way ANOVA with a Tukey's multiple comparison test for (A) and (B), and a two-tailed t-test in (C). Error bars represent SEM; *p < 0.05; **p < 0.01; ***p < 0.001. In addition to the evaluation of COX-derived eicosanoids, a potential role of LTD4 was also investigated through inhibition of 5-LOX, the enzyme responsible for the synthesis of cysLTs 32 . As LTD4 and related LT levels were found to be below the limit of LC-MS/MS detection, and because a commercial LTB4 ELISA gave artifactual readings from brain homogenates, we could not directly quantify inhibition of 5-LOX activity through the measurement of these species. Thus, we chose to investigate the potential use of the dual COX/5-LOX inhibitor, licofelone 35 . Although this compound shows poor blood-brain barrier permeability, preliminary studies showed that 0.6 μ M brain concentrations could be achieved by administering a high dose (0.7 mg/ml) via drinking water to mice. Importantly, this dose led to ~40-50% reductions in COX activity as assessed by measurements of PGE2 and TXB2 in the brains of aged 5XFAD mice (Supplementary Figure 6) . As licofelone has nearly identical IC 50 values for the inhibition of COX-1, COX-2 and 5-LOX 35 , a ~40-50% inhibition of 5-LOX should also occur at this dose. Attempts to further increase the licofelone dose to increase 5-LOX inhibition could not be achieved because of compound insolubility. Thus, licofelone was added at 0.7 mg/ml to drinking water containing SC-560 and rofecoxib, which was administered to 5.5-6-month old 5XFAD mice for 7 days. As expected, nearly complete inhibition of TXB2 and PGE2 production was observed in the treated mice (Supplementary Figure 5) and 0.6 μ M licofelone levels were again achieved in the brain (Supplementary Table 4) , although the mice that received the mixture containing licofelone consumed less water than the groups receiving vehicle or the COX inhibitors only, presumably due to taste aversion since the mice otherwise seemed unaffected, without a significant change in body weight. This resulted in lower SC-560 and rofecoxib brain concentrations than achieved upon treatment with COX inhibitors only (Supplementary Table 4 ). The addition of licofelone to the COX inhibitors resulted in a greater suppression of APP expression in both the cortex (40%; Fig. 8A ) and hippocampus (43%; Fig. 8B ) than obtained with the COX inhibitors alone. However, the difference between the COX-only and COX/Licof treatment groups did not reach statistical significance under these conditions of partial 5-LOX inhibition. Thus, although these data Figure 8 . Inhibition of eicosanoid production reduces APP expression in aged 5XFAD transgenic mice. 5XFAD mice (5.5-6.0 months of age) were provided drinking water containing SC-560 and rofecoxib for a total of 7 days (COX group; 3 females and 6 males). Another group of similarly aged 5XFAD mice received the COX inhibitor mixture supplemented with licofelone (COX/Licof group; 5 females and 4 males). A group of age-matched 5XFAD mice received drinking water containing the vehicle only (5 females and 5 males). Quantification of total APP (22C11 antibody) normalized to GAPDH for cortical (A) and hippocampal (B) homogenates revealed a significant reduction in both the COX and COX/Licof treatment groups compared to the vehicle group. Primary immunoblots are shown for the COX/Licof-treated (CL) and vehicle-treated (V) mice, with lane loading randomized for study blinding during quantification. The 9 COX/Licof inhibitortreated samples were run on each gel, with the 10 vehicle-treated samples split between the two gels. The relative APP/GAPDH value for each drug-treated mouse sample was normalized to the vehicle mean on each gel, with the final APP/GAPDH value consisting of the average sample value derived from the two separate gels. A similar analysis was conducted for the COX inhibitor treatment group. Statistical analyses consisted of a oneway ANOVA with a Tukey's multiple comparison test. *p < 0.05; **p < 0.01, ***p<0.001.
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Interestingly, the reduction in total APP upon treatment of the aged 5XFAD mice with inhibitors of eicosanoid synthesis appeared to result from a decrease in sAPP species, as no changes in intact APP were observed when brain samples were analyzed with the COOH-terminal 5685 APP antibody (Supplementary Figure 7) . However, there was a significant reduction in COOH-terminal APP fragments in the inhibitor-treated 5XFAD mice, without evidence of a preferential reduction of C99 vs. C83 fragments (Supplementary Figure 7) . The coordinate changes in sAPP and COOH-terminal APP fragments are essentially identical to what was observed as the 5XFAD mice aged from 1.5 months to 6.0 months of age. Thus, these data provide further evidence that the increase of APP observed in aged 5XFAD mice results from the age-dependent elevation in eicosanoid levels.
Whereas the reduction of eicosanoids in the aged 5XFAD mice led to a significant diminution of COOH-terminal APP fragments, total Aβ levels in the brains of these mice did not change after the 7 days of drug treatment (Supplementary Figure 8) . As nearly all of the Aβ in 5XFAD mice of this age is within insoluble plaques, it may not be surprising that a short-term reduction in APP would not lead to meaningful change of total Aβ . In fact, this result is consistent with what has been observed in APP transgenic mice treated with a potent β -secretase inhibitor 36 , where reduced Aβ production did not lead to a significant reduction of total Aβ after only one week of dosing.
Discussion
There is value in identifying new mechanisms and targets for regulating Aβ levels in AD brain. In this regard, antagonism of the TP receptor has been suggested as a potential strategy to reduce Aβ production in AD, as activation of this receptor by iPF2α III or TXA2 results in increased APP mRNA and APP protein expression, as well as elevated Aβ release 11, 12 . The TP receptor-mediated increase of APP expression results from mRNA stabilization that does not appear to require 5′ -or 3′ -untranslated sequences, as this effect can be seen in cellular and animal models utilizing APP transgenes lacking these regions 11 . We have further investigated the intracellular pathways responsible for TP receptor-mediated elevation of APP, and reveal the involvement of cPKC isoforms that are activated via Gα q -mediated signaling. The observation that the PKC activator, PMA, increased APP and Aβ production contrasts with earlier studies 37, 38 showing reduced Aβ release after phorbol ester treatment of APP-expressing cells due to increased α -secretase activity. However, these prior studies examined acute phorbol ester treatment, whereas our studies were performed over a longer treatment period. The data presented here are consistent with a prior report 39 of 8 h phorbol ester treatment causing increased APP expression, as well as Aβ production. A key finding from our studies that has important implications for AD is the identification of the EP1, EP3 and CysLT1 receptors as additional Gα q -linked GPCRs that can modulate APP and Aβ expression. This discovery adds to a growing body of evidence implicating glial-derived eicosanoids in AD pathology. For example, genetic knockout of the EP1, EP2 or EP3 receptors has been shown to result in a significant reduction of plaque burden in APP transgenic mice [40] [41] [42] via a number of postulated mechanisms. Similarly, knockout and pharmacological inhibition of the PGE2 EP4 receptor has been reported to reduce plaque burden in an APP Tg mouse model 43 , although an opposite effect was observed in another APP Tg model 44 . There is also evidence of APP regulation in glia via activation of EP2 receptors 45, 46 . Finally, LTD4 injection into mouse brain was shown to increase expression of APP and Aβ 47 , and 5-LOX-derived LTs have also been suggested to contribute to Aβ plaque deposition through an effect on γ -secretase activity 48, 49 . The evidence of eicosanoid contribution to Aβ plaque pathology suggests possible therapeutic strategies to mitigate the effects of these molecules in AD. A dampening of microglial activation might result in the diminished release of these species. However, it could prove difficult to selectively decrease the detrimental aspects of activated microglia without also affecting potential beneficial properties (e.g., Aβ phagocytosis). An alternative approach could be antagonism of eicosanoid receptors, but the evidence implicating multiple neuronal eicosanoid receptors as contributing to the regulation of APP expression and Aβ production presents a multi-target pharmacological challenge. Nonetheless, there may be merit in further exploration of this strategy, as selective antagonism of the most detrimental eicosanoid receptor(s) could provide an effective therapeutic strategy.
Perhaps the most straightforward potential therapeutic strategy to prevent the eicosanoid-driven increases of APP and Aβ in AD would be through inhibition of eicosanoid production, an approach that has been explored with varying results. COX inhibitors have been shown to fairly consistently reduce Aβ pathology in several AD mouse models, although negative reports exist 33, 50, 51 and in some instances reduction of plaques may have resulted in whole or part from the ability of certain non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, to modulate γ -secretase activity 52, 53 . Moreover, although multiple epidemiological studies suggest that non-steroidal anti-inflammatory drug (NSAID) regimens can reduce the incidence of AD 51, 54 , NSAIDs have not generally proven effective in AD clinical trials [55] [56] [57] . There are possible explanations for this lack of clinical success. For example, several of the trials utilized COX-2-selective agents, and it may be COX-1 that is up-regulated upon glial activation in AD 33, 51 . In this regard, asymptomatic individuals treated with the dual COX-1/COX-2 inhibitor naproxen showed some evidence of reduced AD onset 2-3 years after completion of the ADAPT trial, whereas those receiving a COX-2 selective agent did not 58 . Moreover, it is possible that COX inhibition alone may lead to shunting of arachidonic acid to the 5-LOX pathway, resulting in increased production of LTs 59, 60 . This might cause CysLT1 receptor activation and increased APP and Aβ levels, as well as increased Aβ via enhanced γ -secretase cleavage of APP 48, 49 . Thus, the utilization of a combination of COX and 5-LOX inhibitors, or dual-acting COX/5-LOX inhibitors 61 , may merit consideration for AD. It has been reported that 5-LOX and COX levels are increased in the AD brain 32, 48, 62, 63 , and combined COX/5-LOX inhibitors should reduce the production of PGs, TXs and LTs. Furthermore, whereas NSAIDs can cause gastrointestinal or cardiovascular complications, and were poorly tolerated by a percentage of AD patients 64 , dual COX/5-LOX inhibitors such as licofelone appear to have decreased side-effects when compared to typical NSAIDs 35, 65 . Thus, there would appear to be merit in evaluating the effects of prolonged inhibition of both COX and 5-LOX enzymes in APP Tg mouse models of plaque formation to test this therapeutic strategy. However, such an approach would result in a systemic reduction of PGs, TXs and LTs, some of which clearly play a beneficial role within the body, so as with all drugs, a benefit-to-risk assessment would be important if such a strategy were pursued.
In summary, our studies further elucidate how inflammatory eicosanoids might contribute to AD pathogenesis, and provide important new information about GPCR regulation of APP expression. The approximately two-fold increase of APP levels that are observed in culture systems upon activation of the multiple Gα q -linked eicosanoid receptors described herein is consistent with reports of elevated APP in AD brain 66, 67 , as well as the increased APP expression that we observed in plaque-bearing 5XFAD mice. These observations suggest that initial Aβ plaque formation and glial activation in the brain results in the initiation of a vicious cycle, whereby glial-derived eicosanoids may further elevate APP and Aβ expression, thereby accelerating additional plaque deposition. Our data showing that inhibition of eicosanoid synthesis decreases total APP levels and reduces COOH-terminal APP fragments in aged 5XFAD mice supports this cascade hypothesis, and provide impetus to further investigate the contribution of these inflammatory molecules and their receptors to Aβ plaque pathology.
Methods
Cell culture and transfection. QBI293 cells expressing hTP and/or hAPP 12 were grown in DMEM cell culture plus 10% FBS and 1% pen/strep at 37 °C with 5% CO 2 . For studies utilizing siRNA, cells in 6 RNA isolation and qRT-PCR. Cells were washed, lysed, and RNA was isolated according to the RNEasy manufacturer's protocol (Qiagen; Hilden, Germany). RNA (3 μ g) was converted to cDNA using SuperScript III Reverse Transcriptase (Life Technologies; Grand Island, NY). For RT-PCR, the cDNA was diluted 1:8 in water and 7.6 μ L of the product was added to each well containing SYBR Green Master Mix (Life Technologies; Grand Island, NY) and forward and reverse primers at a final concentration that was determined to yield the greatest amplification efficiency (100 nM for APP and 300 nM for all other primer sets). qRT-PCR was run on the Applied Biosystems 7500 Fast Real-time PCR system (Life Technologies; Grand Island, NY) using the Δ Δ C t comparative method of the analyzed gene product vs. GAPDH. The sequences of the primers used for qRT-PCR analysis are shown in Table 1 Immunoblot analysis. Cells were lysed in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40, 5 mM EDTA, pH 8.0) containing a protease inhibitor cocktail (Sigma-Aldrich; St. Louis, MO) and 2 mM PMSF. Lysate was vortexed and then centrifuged at 13,000 x g at 4 °C for 30 min. For examination of APP levels in brains of 5XFAD transgenic mice, cortex and hippocampus were removed from freshly dissected brains obtained from mice euthanized according to protocols approved by the Institutional Animal Care and Use Committee (IACUC). The samples were quick frozen on dry ice, and subsequently homogenized and sonicated in 2% SDS containing the protease inhibitor cocktail and 2 mM PMSF. The homogenates were centrifuged at 40,000 x g for 30 min at room temperature. The supernatants were collected and the pellets were again sonicated in 2% SDS containing protease inhibitors and 2 mM PMSF. After another centrifugation at 40,000 x g for 30 min at room temperature, the supernatant was combined with the initial supernatant. The total protein concentration of cell-or brain-derived samples was determined by BCA assay (Pierce Biotechnologies; Rockford, IL). For most analyses, proteins were separated on 10% SDS-PAGE gels, transferred to nitrocellulose membranes, blocked in blocking buffer (LiCor Biosciences; Lincoln, NE), and incubated overnight with one of the following primary antibodies: APP (amino-terminal, 22C11 68 and Karen
69
; carboxyl-terminal, 5685 31 ); α -tubulin (Covance; Princeton, NJ); GAPDH (Millipore; Billerica, MA); Gα q , Gα 12 , PKCε (Santa Cruz Biotechnologies, Inc.; Dallas, TX); Gα 13 (AbCam; Cambridge, MA); or PKCα (Cell signaling; Danvers, MA). Membranes were washed 3 times for 10 min in Tris-buffered saline and incubated with IRDye 800CW-or 680RD-conjugated 2 o antibodies, followed by imaging and quantification with the Odyssey Imaging System (LI-COR Biosciences; Lincoln, NE). For the analysis of APP and COOH-terminal APP fragments, proteins were separated on 4-12% Bis-Tris gradient gels with MES running buffer (Life Technologies, Grand Island, NY), transferred to nitrocellulose membranes, blocked in 5% milk and incubated overnight with the 5685 APP carboxyl-terminal antibody, followed by treatment with 2 o antibodies as above. Membranes of transfers from 10% gels were routinely cut between the 50 kD and 75 kD molecular weight markers prior to primary antibody incubations so as to allow for independent staining of APP species and housekeeping genes. For studies with 5XFAD transgenic mice, the identity of brain samples were masked prior to gel loading so that the individual conducting immunoblot quantification was unaware of the lane assignments.
Aβ40 and Aβ42 ELISA. Aβ 1-40 and Aβ 1-42 levels were determined by ELISA as previously described 12 . In 2% SDS cortical homogenates from vehicle-or drug-treated 5XFAD mice, the samples were diluted at least 100-fold, such that the final readings fell within the linear portion of a standard curve.
COX and 5-LOX Inhibitor Administration to 5XFAD Transgenic Mice. All mouse studies were approved by the University of Pennsylvania IACUC. Male and female 5XFAD transgenic mice 30 were utilized in these studies, with the age of the mice, the number of mice per group, and their gender distribution listed in the figure legends. The 5XFAD mice express human APP and PS1 that contain 5 mutations associated with familial AD, with germ-line transmission and stable genomic cointegration of both transgenes 30 . Heterozygous male 5XFAD mice (B6/SJL background) were bred with B6/SJL F1 hybrids, and transgenic mice were identified by PCR analysis of tail clips using primers specific for the human APP and human PS1 transgenes. Only mice that were positive for both transgenes were classified as 5XFAD transgenics. Mice from different breedings were grouped together to obtain sufficient group sizes that were within 2 weeks of age. Aged 5XFAD mice were administered either a combination of SC-560 and rofecoxib, a mixture of SC-560, rofecoxib, and licofelone, or vehicle alone for 7 days via drinking water. SC-560 and rofecoxib were formulated at 70 μ g/mL each, and licofelone at 0.7 mg/ml, in 3% (v/v) polyethylene glycol 400, 0.5% (w/v) methyl cellulose 400 cP and 10% (w/v) sucrose. The mice were given ad libitum access to the water.
Quantification of TXB2 and PGE2 in Brain Extracts. PGE2 and TXB2 were extracted from mouse brain homogenates and quantified using stabile isotope dilution (SID) LC-MS/MS. Mouse brain hemispheres were homogenized in 10 mM ammonium acetate buffer pH 5.8 (50% w/v) and extracted essentially as described 70 . Briefly, 3 ml of an acetone/saline solution (2:1) with 0.01% butylated hydroxytoluene (BHT) as an antioxidant was added to 0.1 mL (50 mg) of brain homogenate that had been spiked with 1 ng PGE2-d4 and 1 ng TXB2-d4. This mixture was vortexed for 4 min and then centrifuged at 2000 x g for 10 min. The supernatant was moved to a new tube and 2 ml of hexane was added. After 1 min of vortex mixing and centrifugation as above, the upper hexane phase was discarded. The lower phase was acidified with 30 μ l of 2M acetic acid, followed by the addition of 2 ml of chloroform containing 0.01% BHT. This mixture was vortexed, centrifuged as above, and the lower chloroform phase dried under nitrogen in a 35 °C water bath. Dried samples were reconstituted in 0.1 ml of ethanol for subsequent analysis by LC-MS/MS (Acquity UPLC-TQD; Waters Corporation, Milford, MA, USA). Samples (10 μ L) were separated on a BEH C18 column (1.7 um, 2.1 × 50 mm) using a water/acetonitrile gradient with 0.1% formic acid from 5 to 95% acetonitrile over 5 minutes at 0.6 mL/min and 35 °C. Compounds were detected in negative electrospray ionization mode. Source voltages and MS parameters were optimized for PGE2 and TXB2 during direct infusion of standard solutions (Cayman Chemical, Ann Arbor, MI). Analytes and standards were detected using multiple reaction monitoring of their specific collision induced ion transitions as follows (negative m/z): PGE2 (351 > 271), PGE2-d4 (355 > 275), TXB2 (369 > 169), TXB2-d4 (373 > 173). Standard solutions were prepared with a constant 1 ng of deuterium-labeled internal standard and varying amounts of analyte over concentrations from 1 to 1000 ng/mL. Peak area ratios (analyte/internal standard) were plotted versus standard concentration and a linear regression curve was fit to the data.
Statistics.
Linear mixed-effect models were used to compare the outcomes in cell culture studies when there were three or more treatment groups. The fixed-effects in the linear mixed-effects model were the treatment types and replicate runs, whereas experiment-specific random intercepts were used to account for the correlation between repeated measures within an experiment. Analyses were conducted with SAS v.9.2 (SAS Institute, Inc., Cary, NC). All statistics were two-tailed, with P ≤ 0.05 considered significant. For cell culture or mouse experiments in which only two treatment types were compared, statistical analysis consisted of an unpaired, two-tailed T-test (GraphPad Prism, GraphPad Software, La Jolla, CA). For mouse studies in which three or more treatment conditions were compared, an ANOVA analysis was conducted with either a Dunnett's or Tukey's post-hoc multiple comparison test (GraphPad Prism, GraphPad Software, La Jolla, CA). Detailed statistical outcomes are provided in the Supplementary Materials.
